^
    Back
    Association details:
    Biomarker:PTEN deletion
    Cancer:Melanoma
    Drug Class:Immunotherapy
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Cancers (Basel)
    Title:

    Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients

    Published date:
    08/20/2020
    Excerpt:
    ...we evaluated the NGS results of 82 melanoma patients from clinical routine in 2017….we investigated their potential as a predictor for resistance to immune checkpoint inhibitors (ICI)...A significantly higher incidence of BRAF V600 mutations and EGFR amplifications, PTEN and TP53 deletions was found in patients with disease progression while on ICI.
    DOI:
    https://doi.org/10.3390/cancers12092359